U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06920043) titled 'A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) MASH' on March 26.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Metabolic Dysfunction-Associated Steatohepatitis
Intervention:
DRUG: Efimosfermin
Efimosfermin will be administered as a subcutaneous injection.
DRUG: Placebo
Placebo w...